Welcome to our dedicated page for Tscan Therapeutics news (Ticker: TCRX), a resource for investors and traders seeking the latest updates and insights on Tscan Therapeutics stock.
TScan Therapeutics, Inc. (NASDAQ: TCRX) is a pioneering biopharmaceutical company focused on developing advanced T-cell receptor (TCR) engineered T cell therapies (TCR-T) aimed at treating cancer. Specializing in harnessing novel T cell systems, TScan is at the forefront of extending the promise of immunotherapy to patients with hematologic malignancies and solid tumors.
The company's leading therapies, TSC-100 and TSC-101, are designed to eliminate residual leukemia and prevent relapse in patients with blood cancers such as acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) undergoing hematopoietic stem cell transplantation. These liquid tumor TCR-T therapy candidates are currently in development, reflecting TScan's commitment to improving patient outcomes.
TScan is also developing multiplexed TCR-T therapy candidates for treating various solid tumors, showcasing the company's versatility and innovative approach in the immunotherapy landscape. Recent recognition includes the RMAT designation granted for both TSC-100 and TSC-101, highlighting their potential significance in cancer treatment.
In addition to its groundbreaking therapeutic developments, TScan Therapeutics maintains strong partnerships and a robust financial foundation. The company frequently updates its stakeholders through transparent communication and investor relations, ensuring that all relevant developments and milestones are promptly shared.
For the latest news and updates, you can contact Heather Savelle, VP of Investor Relations, at 857-399-9840 or via email at hsavelle@tscan.com. Further inquiries can also be directed to Joyce Allaire, Managing Director at LifeSci Advisors, LLC, at 617-435-6602 or jallaire@lifesciadvisors.com.
TScan Therapeutics (TCRX) is advancing its T cell receptor-engineered therapies for cancer treatment, focusing on multiplexed TCR-T therapy against solid tumors. The company presented key findings at the SITC Annual Meeting, highlighting the discovery of PRAME-specific TCRs showing strong in vitro and in vivo efficacy. TScan plans to file IND applications for two candidates by the end of 2022 and aims to expand its ImmunoBank for customized therapies. These developments indicate a commitment to addressing tumor heterogeneity and improving treatment outcomes.
TScan Therapeutics (TCRX) announced strong progress in its hematologic malignancies program, with four sites now enrolling patients. The company completed a pre-IND meeting with the FDA for its solid tumor program, indicating a clear path for future IND filings. TScan ended Q3 2022 with $137.3 million in cash, projected to fund operations through Q2 2024. Revenue surged to $3.4 million, up from $2.4 million year-over-year, driven by a collaboration with Novartis. However, TScan reported a net loss of $16.2 million, slightly higher than the previous year.
TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biopharmaceutical company, will host a virtual investor event on November 14, 2022, at 5:00 PM ET. This event will review poster presentations from the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting related to their solid tumor TCR-T candidates. TScan's multiplexed therapy aims to address antigen heterogeneity and HLA loss in cancer treatment. Interested participants can register through the provided link, and a replay will be available on TScan’s website.
TScan Therapeutics, Inc. (TCRX) announced the acceptance of a trial in progress abstract for TSC-100 and TSC-101 at the ASH Annual Meeting scheduled for December 10-13, 2022. The poster presentation, titled 'A Phase 1 Umbrella Study of TCR-Engineered T Cells,' will be presented by Dr. Ran Reshef. TSC-100 and TSC-101 are designed to target HA-1 and HA-2 to prevent relapse in AML, ALL, and MDS patients post-allogeneic transplant. The Phase 1 trial is currently open for enrollment, aiming to improve patient outcomes after reduced-intensity conditioning transplants.
TScan Therapeutics, Inc. (TCRX) announced the acceptance of two abstracts for presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, taking place from November 8–12, 2022, in Boston, MA. The presentations will cover the development of TCR-T therapies targeting MAGEA1 and PRAME to boost therapeutic efficacy, alongside TSC-203-A02, a candidate for treating solid tumors. The company’s ongoing research aims to enhance TCR-T therapeutic options for cancer patients, focusing on both hematologic malignancies and solid tumors.
TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical firm, announced participation in two investor conferences. The Jefferies Cell and Genetic Medicine Summit will take place in New York on September 29, 2022, at 1:30 p.m. ET, followed by Chardan’s 6th Annual Genetic Medicines Conference on October 3, 2022, at 4:00 p.m. ET. Both events will feature fireside chats. Webcasts will be available on the company's website, with archived replays accessible for 30 days post-event.
TScan Therapeutics (TCRX), a clinical-stage biopharmaceutical company, announced a $60 million debt financing facility with K2 HealthVentures. The initial $30 million tranche extends its cash runway into Q2 2024, allowing TScan to pursue key milestones in its clinical programs targeting solid tumors and hematologic malignancies. The terms include an interest rate of 8.75% or the Prime Rate plus 4.75%, and the option for K2HV to convert the loan into TScan common shares at approximately $4.785 each. This partnership aims to enhance TScan’s ImmunoBank and clinical trials.
TScan Therapeutics, Inc. (Nasdaq: TCRX) will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022, at 12:55 p.m. ET in New York, NY. The event will be webcasted, and an archived replay will be available on the company’s website for 30 days. TScan focuses on T cell receptor (TCR) engineered therapies for cancer, with lead candidates TSC-100 and TSC-101 targeting hematologic malignancies. Their ImmunoBank aids in developing customized therapies for various solid tumors.
TScan Therapeutics, Inc. (TCRX) reported its Q2 2022 results, highlighting a revenue increase to $4.1 million from $2.8 million last year, driven by its collaboration with Novartis. The company ended the quarter with $125.6 million in cash, sufficient to fund operations into 2024. The Phase 1 trial for TCR therapies TSC-100 and TSC-101 is now open for enrollment. TScan anticipates IND filings for TSC-200-A2 and TSC-204-C7 by the end of 2022. However, net losses rose to $15.1 million from $10.7 million in the prior year.
TScan Therapeutics, Inc. (Nasdaq: TCRX), a company focused on T cell receptor (TCR) engineered therapies for cancer, will have its CEO, David P. Southwell, participate in a virtual panel at the 13th Annual Wedbush PacGrow Healthcare Conference on August 10, 2022, at 1:10 p.m. ET. This discussion titled “A View to a Kill(er Cell)” will delve into advancements in TCR-T therapies. A webcast of the panel will be available on TScan's website, along with an archived replay for 30 days after the event.
The company is developing TCR-T therapies aimed at hematologic malignancies and solid tumors.
FAQ
What is the current stock price of Tscan Therapeutics (TCRX)?
What is the market cap of Tscan Therapeutics (TCRX)?
What is TScan Therapeutics, Inc.?
What are TScan's leading therapy candidates?
What recent recognition has TScan's therapies received?
What types of cancer does TScan focus on?
How does TScan aim to improve cancer treatment?
How can I contact TScan's Investor Relations?
Where can I get the latest updates about TScan?
What is the stock symbol for TScan Therapeutics, Inc.?
Who are the key contacts for media inquiries at TScan?
What are TScan's goals in immunotherapy?
